Class 4 Medicines Defect Notification: Brilique 90mg Tablets, EL(25)A/18
G Pharma Ltd have informed the MHRA that there is an error in the spelling of the active ingredient included on the imported carton. The spelling should be 鈥楾icagrelor鈥� but has been printed as 鈥楾ricagelor鈥� under the brand name and in the content statement.
DMRC reference number
DMRC-34718431
Marketing Authorisation Holder
G Pharma Ltd
Medicine Details
Brilique 90mg Tablets
PLPI: 16369/2052
Active ingredient: ticagrelor
SNOMED code: N/A
GTIN: 05059053010042
Affected Lot Batch Numbers
| Batch No. | Expiry Date | Pack Size | First Distributed |
|---|---|---|---|
| 200507 (OMB VHVK) | 31/11/2026 | 56 Tablet | 07/10/2024 |
| 200942 (OMB VHXF) | 31/01/2027 | 56 Tablet | 07/10/2024 |
| 201136 (OMB VHXF) | 31/01/2027 | 56 Tablet | 21/10/2024 |
Background
G Pharma Ltd have informed the MHRA that there is an error in the spelling of the active ingredient included on the imported carton. The spelling should be 鈥楾icagrelor鈥� but has been printed as 鈥楾ricagelor鈥� under the brand name and in the content statement.
Advice for Healthcare Professionals
Healthcare professionals are to be aware of the incorrect spelling of the active ingredient on the carton when prescribing and or dispensing the product.
When products from batches included in the table above are supplied or dispensed, please ensure that patients are aware of the spelling mistake on the carton.
The correct spelling of the active ingredient is included in the patient information leaflet and printed on the blister foil within the packs.
Advice for Patients
Patients should continue to take medicines from the impacted batches as prescribed by your healthcare professional. This error does not affect the quality or efficacy of the product.
Patients who experience adverse reactions or have any questions about the medication should seek medical attention. Any suspected adverse reactions should also be reported via the
Additional information
For all medical information enquiries please email ddavies@gpharma.co.uk, or telephone 0161 888 7317. For stock control enquiries please email ddavies@gpharma.co.uk or telephone 0161 888 7317.
Recipients of this Medicines Notification should bring it to the attention of relevant contacts by copy of this notice. NHS regional teams are asked to forward this to community pharmacists and dispensing general practitioners for information.
Yours faithfully
Defective Medicines Report Centre
10 South Colonnade
Canary Wharf
London
E14 4PU
Telephone +44 (0)20 3080 6574
Download document